MarketMoodz
Sanofi's Nexviazyme Baby‑COMET Hits All Phase 3 Endpoints
Sanofi reported that Nexviazyme (avalglucosidase alfa) met all primary and key secondary endpoints in the Phase 3 Baby‑COMET study of treatment‑naïve infants with infantile‑onset Pompe disease (IOPD), including survival without invasive ventilation at 52 weeks. If confirmed by a company release and regulators, the readout could clear a near‑term path to label expansion and lift the commercial outlook for Sanofi’s Pompe portfolio.
Key Takeaways
- Baby‑COMET reportedly met the primary endpoint: proportion alive and free of invasive ventilation at 52 weeks.
- Key secondary endpoints were reportedly met, including survival without invasive ventilation at 12 and 18 months and numerical disease‑measure improvements at 52 weeks.
- The trial was a single‑arm, open‑label study in treatment‑naïve infants aged six months or younger.
- Safety was reported consistent with prior avalglucosidase alfa data: no deaths or treatment‑related serious adverse events and no discontinuations; infusion‑associated reactions occurred in 29.4% and were manageable.
- Sanofi may file for a U.S. label expansion (planned in 2H 2026 per the report), which would expand the addressable patient population if regulators agree.
People Involved
- No specific individuals mentioned
Entities Involved
- Sanofi SA (SNY)Sponsor of Nexviazyme and developer of avalglucosidase alfa
- Nexviazyme (avalglucosidase alfa)Enzyme replacement therapy under study for Pompe disease
- Phase 3 Baby‑COMETSingle‑arm, open‑label trial in treatment‑naïve infants with IOPD
- U.S. Food and Drug Administration (FDA)Regulatory body for a potential U.S. label expansion
- European Medicines Agency (EMA)Regulatory body that has previously reviewed Nexviazyme/Nexviadyme
MarketMoodz Analysis
For investors, a positive Baby‑COMET readout — if confirmed by Sanofi and regulators — is a tangible near‑term catalyst. Expanding Nexviazyme’s label into infantile‑onset Pompe disease could widen the addressable market beyond late‑onset patients, improving revenue visibility for Sanofi’s rare‑disease biologics unit. The safety summary presented (no deaths, no treatment‑related serious AEs, manageable infusion‑associated reactions at 29.4%) reduces one of the main regulatory hurdles, though regulators will want full datasets and longer follow‑up.
Context matters: avalglucosidase alfa is already an approved enzyme replacement therapy, and Sanofi has previously secured approvals in key markets for late‑onset indications. That history should smooth regulatory discussions but doesn’t guarantee approval for IOPD — Baby‑COMET was single‑arm and open‑label, so agencies will scrutinize trial size, endpoints, and comparative benefit. Next steps investors should watch are an official Sanofi press release or regulatory filings with full efficacy and safety tables, dialogue with the FDA/EMA, and any updates to the company’s submission timeline (the 2H‑2026 U.S. filing in the report remains unconfirmed).
Market reaction will hinge on confirmation and detail: a clean company release and a clear regulatory pathway could lift sentiment and re‑rate Sanofi’s rare‑disease franchise; incomplete data or regulatory requests for additional evidence could mute upside. Also monitor unrelated regulatory or antitrust developments involving Sanofi to avoid conflating separate risks with the Nexviazyme story.
Source: Original Article